AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8083713 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate at 150 mg/m2/d
Number of subjects: 36
Study 8083713 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (various doses: 50, 75, 100, 125, 150, 175, and 200 mg/m2/d)
Number of subjects: 36
Study 8083713 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate
Number of subjects: 36
Study 8083713 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 36
Study 8083713 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate and etoposide
Number of subjects: 36
Study 2587982 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol spray
Number of subjects: 0
Study 1234503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (20 mg)
Number of subjects: 0
Study 1234503 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0
Study 1234503 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide hydrochloride (20 mg)
Number of subjects: 0
Study 31422111 — intervention group
Group type: EXPERIMENTAL
Intervention: CA125-guided diuretic treatment
Number of subjects: 160
Study 31422111 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study 30844137 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor relationship consensus
Number of subjects: 60
Study 30844137 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship cohesion
Number of subjects: 60
Study 30844137 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship satisfaction
Number of subjects: 60
Study 28358246 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct renin inhibition (DRI)
Number of subjects: 24
Study 28358246 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin receptor blocker (ARB)
Number of subjects: 24
Study 25933495 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (HF; 46 g fat, 1210 kcal)
Number of subjects: 17
Study 25933495 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal (LF; 15 g fat, 1214 kcal)
Number of subjects: 17
Study 25933495 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy meal (HF or LF)
Number of subjects: 17
Study 24468780 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg of eravacycline/kg intravenously every 12 h for a total of seven doses over 4 days
Number of subjects: 20
Study 24468780 — intervention group
Group type: EXPERIMENTAL
Intervention: Eravacycline concentrations in ELF at 2, 4, 6, and 12 h
Number of subjects: 20
Study 24468780 — intervention group
Group type: EXPERIMENTAL
Intervention: Eravacycline concentrations in AM at 2, 4, 6, and 12 h
Number of subjects: 20
Study 24468780 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of eravacycline concentrations in ELF and AM to plasma
Number of subjects: 20
Study 22999793 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 30
Study 22999793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22999793 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin stimulation
Number of subjects: 30
Study 19651060 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (EST)
Number of subjects: 211
Study 19651060 — intervention group
Group type: COMPARATOR
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 211
Study 17489325 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (monthly injection, group 1; n = 40)
Number of subjects: 80
Study 17489325 — intervention group
Group type: COMPARATOR
Intervention: Surgical castration (pulpectomy, group 2; n = 40)
Number of subjects: 80
Study 15278236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB)
Number of subjects: 0
Study 15278236 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly sensitive diagnostic tools (RT-PCR)
Number of subjects: 0
Study 15278236 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative or conservative therapies in sentinel node-positive patients
Number of subjects: 0
Study 11309436 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized-treatment arm (40 mg mitomycin C with pharmacokinetic manipulations and urine alkalinization)
Number of subjects: 230
Study 11309436 — intervention group
Group type: COMPARATOR
Intervention: Standard-treatment arm (20 mg mitomycin C without pharmacokinetic manipulations or urine alkalinization)
Number of subjects: 230
Study 9674777 — intervention group
Group type: EXPERIMENTAL
Intervention: High vagus nerve stimulation
Number of subjects: 196
Study 9674777 — intervention group
Group type: COMPARATOR
Intervention: Low vagus nerve stimulation
Number of subjects: 196
Study 7489167 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic catheterization
Number of subjects: 57
Study 7489167 — intervention group
Group type: COMPARATOR
Intervention: Urethral catheterization
Number of subjects: 57
Study 2023746 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminocaproic acid (Amicar) 50 mg/kg every 4 hours for 5 days (max 30 g daily)
Number of subjects: 112
Study 2023746 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 40 mg daily (adjusted for weight) in two divided doses
Number of subjects: 112
Study 6452796 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 6452796 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 0
Study 6452796 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline-N-oxide
Number of subjects: 0
Study 6452796 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 6452796 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine-N-oxide
Number of subjects: 0
Study 6452796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine (large doses)
Number of subjects: 0
Study 6452796 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (75 mg)
Number of subjects: 0
Study 6452796 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (150 mg)
Number of subjects: 0
Study 6452796 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (225 mg)
Number of subjects: 0
Study 6452796 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (300 mg)
Number of subjects: 0
Study 30850099 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 98
Study 30850099 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 98
Study 28848225 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide supplementation (up to a maximum of 3 times 450 mg daily)
Number of subjects: 52
Study 28848225 — intervention group
Group type: COMPARATOR
Intervention: No supplements (Control)
Number of subjects: 52
Study 28848225 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 52
Study 24580722 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong identification with employer
Number of subjects: 100
Study 24580722 — intervention group
Group type: COMPARATOR
Intervention: Single and multiple organizational sources
Number of subjects: 100
Study 23398554 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapler A (CPH32; Frankenman International Ltd, Hong Kong, China)
Number of subjects: 50
Study 23398554 — intervention group
Group type: COMPARATOR
Intervention: Stapler B (PPH03; Ethicon Endo‐Surgery, Spreitenbach, Switzerland)
Number of subjects: 50
Study 21444144 — intervention group
Group type: EXPERIMENTAL
Intervention: Manually operated hand‐powered mechanical resuscitation device (MRD)
Number of subjects: 80
Study 21444144 — intervention group
Group type: COMPARATOR
Intervention: Standard single rescuer basic life support (BLS)
Number of subjects: 80
Study 19323865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-operated weight-loss programme (n=62)
Number of subjects: 125
Study 19323865 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group, n=63)
Number of subjects: 125
Study 17452151 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue percutaneous coronary intervention (rPCI)
Number of subjects: 307
Study 17452151 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 307
Study 15291660 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 179
Study 15291660 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 179
Study 15291660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 15291660 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 179
Study 11133624 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.078 microg/mL sufentanil
Number of subjects: 328
Study 11133624 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.156 microg/mL sufentanil
Number of subjects: 328
Study 11133624 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.312 microg/mL sufentanil
Number of subjects: 328
Study 11133624 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.468 microg/mL sufentanil
Number of subjects: 328
Study 11133624 — intervention group
Group type: COMPARATOR
Intervention: No sufentanil
Number of subjects: 328
Study 9439023 — intervention group
Group type: EXPERIMENTAL
Intervention: Grunge rock music
Number of subjects: 144
Study 9439023 — intervention group
Group type: EXPERIMENTAL
Intervention: Designer music
Number of subjects: 144
Study 9439023 — intervention group
Group type: EXPERIMENTAL
Intervention: New Age music
Number of subjects: 144
Study 9439023 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 144
Study 8021737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide (VP-16) at 50 mg/m2
Number of subjects: 20
Study 8021737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide (VP-16) at 60 mg/m2
Number of subjects: 20
Study 8021737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide (VP-16) at 75 mg/m2
Number of subjects: 20
Study 2915763 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine therapy (1 g i.v.) at the end of dialysis for 1 month, followed by L-carnitine added to the dialysate (2 g in group 1, 4 g in group 2) for 3 months
Number of subjects: 22
Study 2915763 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine added to the dialysate (2 g in group 1, 4 g in group 2)
Number of subjects: 22
Study 2915763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of L-carnitine (2 g)
Number of subjects: 22
Study 31968346 — intervention group
Group type: EXPERIMENTAL
Intervention: MCO HD
Number of subjects: 89
Study 30169840 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency spinal cord stimulation (HF-SCS) at 10 kHz
Number of subjects: 5
Study 28526046 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain balloon angioplasty with or without bail-out bare metal stenting
Number of subjects: 861
Study 28526046 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon angioplasty with or without bail-out bare metal stenting
Number of subjects: 861
Study 28526046 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting with drug-eluting stents
Number of subjects: 861
Study 25623382 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser treatment (L group)
Number of subjects: 19
Study 25623382 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (C group)
Number of subjects: 19
Study 23010700 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucralfate ointment
Number of subjects: 48
Study 21169874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto‐Wolfberry (LWB) 13.7 g/d for 90 days
Number of subjects: 75
Study 21169874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 18349190 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile display group
Number of subjects: 24
Study 18349190 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard monitoring alone)
Number of subjects: 24
Study 16600227 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium buffered with HEPES
Number of subjects: 708
Study 16600227 — intervention group
Group type: COMPARATOR
Intervention: Medium buffered without HEPES
Number of subjects: 708
Study 14637332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal (Cheerios or Shreddies)
Number of subjects: 29
Study 14637332 — intervention group
Group type: COMPARATOR
Intervention: Glucose drink
Number of subjects: 29
Study 14637332 — intervention group
Group type: COMPARATOR
Intervention: No breakfast
Number of subjects: 29
Study 10627328 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-support in healthy subjects
Number of subjects: 0
Study 10627328 — intervention group
Group type: COMPARATOR
Intervention: No arm-support in healthy subjects
Number of subjects: 0
Study 10627328 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of quadriceps in paraplegic patients
Number of subjects: 0
Study 10627328 — intervention group
Group type: COMPARATOR
Intervention: No electrical stimulation in paraplegic patients
Number of subjects: 0
Study 9177507 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid infusion (0.1 N HCl at 6-8 cc/min)
Number of subjects: 21
Study 9177507 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (0.9 N saline)
Number of subjects: 21
Study 8247818 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity protocol
Number of subjects: 15
Study 8247818 — intervention group
Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 15
Study 8247818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 15
Study 8247818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular fitness
Number of subjects: 15
Study 2859047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro31-1118 (10 mg orally)
Number of subjects: 16
Study 2859047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro31-1118 (20 mg orally and intravenously)
Number of subjects: 16
Study 2859047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro31-1118 (40, 80, 160, and 320 mg orally)
Number of subjects: 16
Study 2859047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro31-1118 (320 mg)
Number of subjects: 16
Study 2859047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro31-1118 (not specified dose)
Number of subjects: 16
Study 2859047 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg)
Number of subjects: 16
Study 2859047 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 16
Study 31444861 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient hyaluronic acid dermal filler
Number of subjects: 140
Study 31444861 — intervention group
Group type: COMPARATOR
Intervention: Comparator filler
Number of subjects: 140
Study 28759275 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with depressive symptoms (CES-D score ≥ 16)
Number of subjects: 599
Study 28759275 — intervention group
Group type: COMPARATOR
Intervention: Subjects without depressive symptoms (CES-D < 16)
Number of subjects: 599
Study 28759275 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-white subjects
Number of subjects: 599
Study 28759275 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function (FEV1%) and asthma control
Number of subjects: 599
Study 26956551 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone pretreatment (10 mg transdermal gel for 21 days)
Number of subjects: 50
Study 26956551 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 50
Study 24168317 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring with the Dexcom G4 PLATINUM communicating with the Diabetes Assistant
Number of subjects: 20
Study 24168317 — intervention group
Group type: COMPARATOR
Intervention: Usual wear of a Dexcom G4 PLATINUM CGM system
Number of subjects: 20
Study 24168317 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 20
Study 23152846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger preparation
Number of subjects: 64
Study 23152846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 20186829 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ghrelin (13 microg/kg daily)
Number of subjects: 31
Study 20186829 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ghrelin (0.7 microg/kg daily)
Number of subjects: 31
Study 17595201 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 425
Study 17595201 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Amoxicillin
Number of subjects: 425
Study 17595201 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 infected children <12 months
Number of subjects: 425
Study 17595201 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 infected children
Number of subjects: 425
Study 17595201 — intervention group
Group type: COMPARATOR
Intervention: HIV exposed uninfected children
Number of subjects: 425
Study 16327738 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of the EORTC QLQ-SAT32 questionnaire
Number of subjects: 123
Study 16327738 — intervention group
Group type: COMPARATOR
Intervention: Interview administration of the EORTC QLQ-SAT32 questionnaire
Number of subjects: 123
Study 11926620 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapeseed extract (GSE) 100 mg, twice daily
Number of subjects: 0
Study 11926620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9927239 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7653811 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine (1 mg/kg)
Number of subjects: 50
Study 7653811 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (15 mg/kg)
Number of subjects: 50
Study 2519572 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin-hMG
Number of subjects: 35
Study 2519572 — intervention group
Group type: COMPARATOR
Intervention: FSH-hMG
Number of subjects: 35
Study 28719078 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin (2.5 mg, newly administered)
Number of subjects: 32
Study 28719078 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1500 mg, newly or additionally administrated)
Number of subjects: 32
Study 26849997 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD (200 μg)
Number of subjects: 16
Study 26849997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24908387 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary transition to oral methadone
Number of subjects: 95
Study 23652909 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 20 mg orally once daily for 3 months
Number of subjects: 30
Study 23652909 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (glucose capsules) for 3 months after isotretinoin therapy
Number of subjects: 30
Study 23652909 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin therapy
Number of subjects: 30
Study 20053975 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous humor from RP patients
Number of subjects: 15
Study 20053975 — intervention group
Group type: COMPARATOR
Intervention: Aqueous humor from control group (patients undergoing cataract surgery)
Number of subjects: 15
Study 18428023 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute insulin response (AIR)
Number of subjects: 171
Study 18428023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity index (S(I))
Number of subjects: 171
Study 16132058 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml/day of Sicilian red wine for 4 weeks
Number of subjects: 48
Study 16132058 — intervention group
Group type: COMPARATOR
Intervention: Usual wine intake for 4 weeks
Number of subjects: 48
Study 12972981 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 pulses per second (PPS; n=13)
Number of subjects: 24
Study 12972981 — intervention group
Group type: COMPARATOR
Intervention: 200 pulses per second (PPS; n=11)
Number of subjects: 24
Study 12972981 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (50 PPS and 200 PPS)
Number of subjects: 24
Study 10838463 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet alone (80% of predicted needs)
Number of subjects: 38
Study 10838463 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet + resistance exercise + casein protein (1.5 g/kg/day)
Number of subjects: 38
Study 10838463 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet + resistance exercise + whey protein hydrolysate
Number of subjects: 38
Study 9349888 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial resection of the first annular pulley
Number of subjects: 19
Study 9349888 — intervention group
Group type: COMPARATOR
Intervention: Standard complete first annular pulley release
Number of subjects: 19
Study 8251808 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate
Number of subjects: 510
Study 8251808 — intervention group
Group type: COMPARATOR
Intervention: Beta carotene
Number of subjects: 510
Study 3102375 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with ultrasound
Number of subjects: 154
Study 3102375 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy without ultrasound
Number of subjects: 154
Study 30633580 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplements (ONS)
Number of subjects: 100
Study 30633580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ONS)
Number of subjects: 100
Study 27351629 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccade training (experimental)
Number of subjects: 25
Study 27351629 — intervention group
Group type: COMPARATOR
Intervention: Reading training (control)
Number of subjects: 25
Study 23834666 — intervention group
Group type: EXPERIMENTAL
Intervention: BAX326 (recombinant factor IX); Dosage: 49.5 (±4.8) IU kg(‐1) per infusion, administered twice weekly for a mean duration of 6.2 (±0.7) months
Number of subjects: 73
Study 23834666 — intervention group
Group type: EXPERIMENTAL
Intervention: BAX326 (recombinant factor IX); used for controlling acute bleeds
Number of subjects: 73
Study 23834666 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (on-demand treatment)
Number of subjects: 73
Study 21764558 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 questionnaire
Number of subjects: 120
Study 20070299 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year maintenance after a 6-week cycle of early intravesical chemotherapy (epirubicin, 80 mg/50 mL)
Number of subjects: 482